Crown Laboratories Acquires Revance Therapeutics for $924 Million in Cash

Wrinkle-reducing injection manufacturer Revance Therapeutics Inc. (RVNC) entered a merger agreement on August 12, 2024, to be taken private by privately held Crown Laboratories, Inc. in a deal valued at $924 million, including debt.

Deal Structure:

Under the terms of the agreement, Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $6.66 per share in cash, representing a premium of 88.67% from the stock’s last close.

Please subscribe for free or login to your InsideArbitrage account to access this article.